# SYS6002 vs Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

> **NCT07526792** · PHASE3 · NOT_YET_RECRUITING · sponsor: **CSPC Megalith Biopharmaceutical Co.,Ltd.** · enrollment: 406 (estimated)

## Conditions studied

- Urothelial Carcinoma

## Interventions

- **DRUG:** SYS6002
- **DRUG:** Investigator's Choice of Chemotherapy

## Key facts

- **NCT ID:** NCT07526792
- **Lead sponsor:** CSPC Megalith Biopharmaceutical Co.,Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-20
- **Primary completion:** 2029-06-01
- **Final completion:** 2029-12-01
- **Target enrollment:** 406 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07526792

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07526792, "SYS6002 vs Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07526792. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*